Zymeworks To Report Third Quarter 2024 Financial Results and Host Conference Call on October 31, 2024
Dr. Raffaele Colombo Honored as a PharmaVoice 100 Winner
Zymeworks is thrilled to announce that Dr. Raffaele Colombo has been honored as a PharmaVoice 100 winner. This annual list recognizes the most inspiring people in the life sciences industry. Dr. Colombo has been instrumental in the advancement of Zymeworks’ wholly-owned pipeline, leveraging his experience and knowledge towards the development of a portfolio of novel […]
Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference
Zymeworks Announces Participation in Upcoming Investor Conferences
Zymeworks To Report Second Quarter 2024 Financial Results and Host Conference Call on August 1, 2024
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW171, a novel 2+1 T-cell Targeting Bispecific Antibody for Mesothelin-expressing Cancers
Zymeworks Announces China NMPA Acceptance of Biologics License Application for Zanidatamab for Second-Line Treatment of Biliary Tract Cancer
Zymeworks Announces Participation in Upcoming Investor Conferences
Zymeworks Provides Corporate Update and Reports First Quarter 2024 Financial Results
Zymeworks Announces Participation in Upcoming Investor Conferences
Zymeworks To Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024
Zymeworks Announces Appointment of Dr. Neil Gallagher to its Board of Directors
